8.30AM - 03.40PM EDT | 5.30AM - 12.40PM PDT

9:00 am Preconference Virtual Networking

Overcoming Regulatory Restrictions at Home and Abroad

9:30 am FDA Regulation of Cannabinoid Pharmaceuticals – Breaking Down All Possible Routes to Approval

  • Dominic Chiapperino Director - Controlled Substances Division, US Food & Drug Administration (FDA)

9:50 am The International Drug Control Landscape for Cannabinoid Derived Pharmaceuticals

  • Pavel Pachta Director for International Regulatory Affairs, International Cannabis and Cannabinoids Institute (ICCI)

10:10 am Rx and Non-Rx Cannabinoids: A Regulatory Framework for Market

10:30 am Live Presenter Q&A

  • Dominic Chiapperino Director - Controlled Substances Division, US Food & Drug Administration (FDA)
  • Pavel Pachta Director for International Regulatory Affairs, International Cannabis and Cannabinoids Institute (ICCI)
  • Rob Dhoble Managing Director, Havas ECS

10:50 am Morning Break & Virtual networking

11:20 am Case Study: Brazilian Cannabis Regulation and its Impact for the Companys’ Clinical Trials Pipeline

11:40 am Key Regulatory Takeaways in Developing a Cannabinoid Pharmaceutical Development Strategy

  • Bruce Mackler Executive Vice President, Regulatory Affairs, Ethicann Pharmaceuticals

12:00 pm Live Presenter Q&A

  • Caio Santos Abreu Founder & Chief Executive Officer , Entourage Phytolab
  • Bruce Mackler Executive Vice President, Regulatory Affairs, Ethicann Pharmaceuticals

Achieving Market Exclusivity and Building an IP Strategy

12:20 pm Cannabinoid-Related IP: Novelty Amidst a Treasure Trove

12:40 pm Live Presenter Q&A

12:50 pm Panel Discussion: Designing an IP Strategy from the Ground Up that Will Give you the Edge

1:20 pm Lunch & Virtual Networking

Breaking Down Barriers to Investment

1:50 pm Panel Discussion: Dispelling Common Misconceptions About Biotech Funding and Applying this Understanding to Cannabinoid Pharmaceuticals

14.30 Afternoon Virtual networking Break 

Translational Clinical Development Track

Commercial Pipeline Development and Manufacturing Track

Efficiently take your cannabinoid formulation from in vivo/vitro testing into the clinic, with confidence

Maximizing the value that your therapeutics offer and ensuring quality in your supply chain

3.00 pm Assessing the Potential Clinical Value of the Next Hopefuls in Cannabinoid Pharmaceutical APIs: CBG, CBN and THCA

  •  Preclinical evidence for the use of novel minor cannabinoids
  • Minor cannabinoid safety and toxicity
  • Where is the clinical evidence?

Hunter Land, Associate Director of Cannabinoid Research, Canopy Growth Corporation

3.00 pm Analyzing Clinical Data to Extract Insights into Clinical Endpoints and Mechanism of Action

  • Tetra Biopharma is currently pursuing a variety of clinical programs employing inhaled synthetic cannabinoid derived pharmaceuticals, including for pain and oncology indications
  • Analysis, interpretation and comparison of data across programs also connects these and is invaluable for the design of future studies and in decision making when it comes to future indications to pursue

Aurélia De Pauw, Vice President, Clinical Programs and Medical Affairs, Tetra Bio Pharma

3.20 pm How can you Accelerate and Support the Preclinical & Translational Development of Therapeutics in this Space?

  • The cannabinoid derived drug development industry is facing multiple roadblocks impeding the demonstration of clinical utility in pipeline candidates
  • Highlight your proven track record facilitating and accelerating the delivery of therapeutics with target efficacy and safety profiles
  • Position yourself as the partner of choice in this fast paced and expanding industry
    Enquire today to find how you can get involved and
    contact:
    Nicholas Ramovic, Partnerships Director
    @: sponsor@hansonwade.com
    T: (+1) 617 455 4188

3.20 pm Strategically Selecting New Indications to Pursue

  • Which data can be used to inform future therapeutic indications to pursue
  • Clinical trial data for expanding the indications of existing pharmaceuticals
  • Regulatory considerations in cannabis-based pharmaceutical development

Boaz Hirshberg, Executive Vice President, Chief Medical Officer, Head of Global Development, BOLPharma

3:40 pm Chair’s Closing Remarks & End of Conference